NEW YORK, Jan. 12, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) (“NeoStem” or the “Company”), an international biopharmaceutical company with operations in the U.S. and China, today announced that Dr. Robin Smith, the Company’s Chairman and CEO, will present on Wednesday, January 12, 2011 at the OneMedForum 2011 at 9:15 AM PST and at the Biotech Showcase 2011 at 11:00 AM PST. Both events will be held in San Francisco, California.
The OneMedForum 2011 will be held at the Sir Francis Drake Hotel at 450 Powell Street, San Francisco, CA and Dr. Robin Smith will present in the Renaissance Room. The Biotech Showcase 2011 will be held at Parc 55 Wyndham San Francisco, CA and Dr. Robin Smith will present in the Stockton Room.
In recapping highlights of 2010, the Company will review its multiple accomplishments for the year. In November 2010, we raised $19 million from two concurrent offerings. These funds will help us to grow our revenue lines of businesses in the US and China, including the closing of our acquisition of Progenitor Cell Therapy LLC, and further assist in our growth. NeoStem was also named “Best Stem Cell Company, 2010" in The New Economy’s Biotech Awards. Additionally, The Vatican’s Pontifical Council has undertaken to commit $1 million to joint ventures with NeoStem and the Stem for Life Foundation, a not-for-profit entity NeoStem participated in founding, to expand research and raise awareness of adult stem cell therapies.
We also began generating revenues from what we believe will be just the beginning of a pipeline of stem cell-based regenerative medicine therapies, a key element of our growth strategy in both the United States and China, with our collaboration with Wendeng Hospital in China whereby patients are being offered the benefit of the latest technology from the US in the treatment of a range of orthopedic conditions. Additionally, the ongoing relocation to Suzhou Erye Pharmaceutical’s new manufacturing facility continues to progress and should be completed in 2011 thereby significantly increasing capacity.
“I look forward to the opportunity to detail some of these exciting developments as well as discuss some of our upcoming milestones at these two industry events in San Francisco,” said Dr. Robin Smith.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company also has licensed various stem cell technologies, including a worldwide exclusive license to VSEL Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem’s majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com.
About the Biotech Showcase (Innovation Opportunity Collaboration)
Now in its third year, Biotech Showcase will feature corporate presentations by 195 innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. The showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. More can be found on their website: http://www.ebdgroup.com/bts/index.php.
About OneMedForum
Founded in 2008, OneMedForum events are held biannually in San Francisco in January and in New York in June. They are designed to create a communications platform for emerging companies to connect with strategic partners and investors.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company’s strategy, as well as other advances in the Company’s business, about which no assurances can be given. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010 as well as other periodic filings made with the Securities and Exchange Commission. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
For more information, please contact: | |
NeoStem, Inc. | |
Robin Smith, CEO | |
Phone: +1-212-584-4174 | |
Email: rsmith@neostem.com | |
SOURCE NeoStem, Inc.
